- Novavax COVID-19 vaccine gets emergency use authorization in US
- FDA Fast Track Designation = Immediate Surge in Stock Prices?
- France Resumes COVID-19 Vaccination Campaign
- Why did Early American Settlers stuggling with “Prairie Madness”?
- Largest Healthcare Group in the US Initiates Strike
- Targeting Sugar Molecules in Sugar-Immune Therapy
Nature: Pfizer mRNA COVID-19 vaccine can neutralize mutant strains and protect people who have not been vaccinated
Nature: Pfizer mRNA COVID-19 vaccine can neutralize mutant strains. With the emergence of new variants of the new coronavirus, it is urgent to evaluate the immune effects of existing vaccines to produce antibodies and neutralize these variants.
Nature: Pfizer-BioNTech COVID-19 mRNA Vaccine Can Neutralize New Variant Strains
With the emergence of new variants of the new coronavirus, it is urgent to evaluate the immune effects of existing vaccines to produce antibodies and neutralize these variants. The World Health Organization (WHO) has designated B.1.617.2 as the new coronavirus mutant strain that needs attention, and B.1.525 as the mutant strain that needs attention.
On June 10, 2021, Peiyong Shi and others from the University of Texas in the United States published a research paper titled “BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants” in Nature, confirming that Pfizer was inoculated-BioNTech The serum of the mRNA new coronavirus vaccine neutralized the new new coronavirus mutant.
The sera of people vaccinated with two doses neutralized B.1.617.2 (also known as the delta variant, first found in India) and some other variants, including B.1.525 (first found in Nigeria).
The research team used 20 serum samples from fifteen people who had received 2 doses of Pfizer-BioNTech vaccine to test the neutralizing activity of the serum against recombinant new coronaviruses. These viruses expressed B.1.617.2 and B.1.617. .1 Spike protein of B.1.618 (first discovered in India) and B.1.525 mutant strains.
Compared with the virus strain isolated in January 2020, the serum has lower activity against the mutant strains-especially the B.617.1 mutant strain-but the study has observed that the serum has a robust neutralizing effect on all tested mutant strains. The authors concluded that this finding suggests that the vaccine may provide adequate protection against these new variants.
The author compared these results with the vaccine’s test on the B.1.351 variant (also known as the β variant, found in South Africa), and found that there was a decrease in neutralizing activity similar to that of B.1.617.1, but the vaccine still showed resistance. B.1.351 75% effectiveness for infections and 100% effectiveness for serious or fatal diseases.
The authors concluded that the report on the effectiveness of the vaccine against variant strains shows the importance of the vaccination schedule, which may reduce the emergence of new variant strains.
Nature Medicine: COVID-19 vaccine can protect people who have not been vaccinated
Clinical trials and vaccination plans show that Pfizer-BioNTech’s mRNA COVID-19 vaccine is effective in preventing infection and disease at the individual and community levels. However, studies have also shown that vaccination may cause changes in human behavior and increase infectivity.
For example, people who have been vaccinated may not pay much attention to maintaining social distancing or not actively isolate themselves after contact with COVID-19 patients.
On June 10, 2021, researchers from the Technion-Israel Institute of Technology published a research paper titled “Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals” in Nature Medicine.
The study found that the high vaccination rate of the COVID-19 lung vaccine is related to the low infection rate of the new coronavirus in people aged 16 and under. Researchers analyzed the vaccination records and test results of 177 geographic and different communities in Israel from December 6, 2020 to March 9, 2021, and showed that the COVID-19 vaccination can not only protect those who have been vaccinated, but also protect those who have not been vaccinated. By.
Israel began to receive the COVID-19 vaccine (mainly Pfizer-BioNTech’s mRNA vaccine) from December 19, 2020, and covered nearly 50% of the population within 9 weeks. In order to clarify whether vaccination can reduce the spread of the new coronavirus among unvaccinated individuals at the group level, the author of the paper studied 177 communities with different geographic locations and different vaccination rates (a total of 1.37 million people received the first dose), and A group of unvaccinated groups under the age of 16 who have not yet been vaccinated.
The author counted the changes in the number of COVID-19 positives in each community at regular intervals. They found that, on average, for every 20% increase in the number of vaccinated people in a community, the number of COVID-19-positive people in the same community who had not been vaccinated would roughly triple.
The authors reminded that their results did not consider the population’s natural immunity to the new coronavirus. The author concludes that although it is exciting to see vaccine-related protection in unvaccinated people, further research is needed to understand how vaccination programs can help achieve herd immunity and eliminate diseases.
(source:internet, reference only)